Engaging the Immune System Against Disease, Andrew Allen, Co-Founder, President & CEO, Gritstone bio
Synopsis:
Andrew Allen, M.D., Ph.D., is the Co-Founder, President and CEO of Gritstone bio, a clinical-stage biotech company developing groundbreaking immunotherapies for cancers and infectious diseases. Gritstone seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. Andrew joins host Rahul Chaturvedi for a conversation about his entrepreneurial journey founding a biotech, the state of biotech right now and how he manages his team during times of volatility. He also discusses the exciting science they’re pursuing at Gritstone and the role T cells play in engaging the immune system against cancer and infectious diseases.
Biography:
Andrew Allen, M.D., Ph.D. co-founded Gritstone bio, Inc. and has served as President, CEO and a board member since 2015. In 2009, Dr. Allen co-founded Clovis Oncology and served as Chief Medical Officer until 2015, driving development of Rucaparib, a PARP inhibitor. Prior he was Chief Medical Officer at Pharmion Corporation, developing Vidaza, the first approved DNA methylation inhibitor, until acquisition by Celgene in 2008. Dr. Allen also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company. He currently serves on the board of directors of TCR2 Therapeutics and Sierra Oncology (both public biopharma companies) and Revitope Oncology and Verge Genomics (both private biopharma companies). He previously served on the board of directors of Epizyme (developers of the first approved histone methylation transferase inhibitor) and Cell Design Labs (acquired by Gilead Sciences in 2017). Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London.